PERSON
Vertex’s Non-Opioid Pain Drug, Suzetrigine (VX-548), Shows Promising Results in Phase III Trials, Aiming for FDA Approval
Non-opioid pain drug, Suzetrigine (VX-548), Vertex Pharmaceuticals, Phase III trials, acute pain, FDA approval, opioid alternative
FDA Approves Avadel’s Lumryz for Pediatric Narcolepsy Patients
Avadel Pharmaceuticals, Lumryz, narcolepsy, pediatric patients, FDA approval, sodium oxybate, cataplexy, excessive daytime sleepiness (EDS)
FDA Approves Novocure’s Optune Lua for Metastatic Non-Small Cell Lung Cancer Treatment
Optune Lua, FDA approval, metastatic non-small cell lung cancer, Tumor Treating Fields, Novocure, NSCLC treatment.
Novocure’s Optune Lua Wins FDA Approval for Metastatic Non-Small Cell Lung Cancer Treatment
Novocure, Optune Lua, FDA approval, metastatic non-small cell lung cancer, TTFields, lung cancer treatment, PD-1/PD-L1 inhibitors, docetaxel.
Pfizer and Triana Biomedicines Collaborate on Molecular Glue Discovery for Cancer and Other Diseases in $1.5 Billion Deal
Pfizer, Triana Biomedicines, molecular glue, cancer, oncology, drug discovery, biotechnology, pharmaceuticals
Jasper Therapeutics Escalates Dose in Hives Trial Following Rapid Complete Responses
Jasper Therapeutics, briquilimab, chronic inducible urticaria, hives, dose escalation, clinical trial, SPOTLIGHT study
B. Braun’s Florida IV Fluid Plant Resumes Operations After Minimal Damage from Hurricane Milton
B. Braun, Hurricane Milton, IV Fluids, Florida Facility, Supply Chain
Leo Pharma Announces Major Restructuring with Up to 250 Layoffs and Relocations
Leo Pharma, layoffs, relocations, restructuring, biopharma, job cuts
Arda Therapeutics Secures $43M Series A Funding to Pioneer ADCs for Fibrotic Diseases
Arda Therapeutics, Series A Funding, Fibrotic Diseases, Antibody-Drug Conjugates (ADCs), Eli Lilly, Andreessen Horowitz (a16z)
Vanqua Bio Advances Experimental Parkinson’s Therapy with VQ-101, Bolsters Leadership Team
Vanqua Bio, VQ-101, Parkinson’s disease, GBA gene mutations, GCase activator, Neurodegenerative diseases, Clinical trials, Lysosomal dysfunction, Alpha-synuclein accumulation